Coach Chris Howell's peptide therapy claims, fact-checked

What did @coachchrishowell actually say?

The core argument here is that injection site selection changes how BPC-157 and TB-500 perform, and that pre-mixed blends force a compromise. The creator claims subcutaneous injection near an injury delivers BPC-157 with "higher regional concentration at the target tissue," while TB-500 works better intramuscularly because it operates systemically. He then softens the landing: pre-mixed subcutaneous abdominal injection is "a sound and well supported approach" that still produces results.

He also draws a clear distinction between the two peptides. BPC-157 is described as derived from a gastric protein and linked to tendon repair, gut integrity, and angiogenesis. TB-500 is positioned as a systemic recovery peptide tied to actin regulation and cell migration. These characterizations are broadly consistent with preclinical literature, though the framing deserves scrutiny.

Does the science back this up?

Partially, but the confidence level in the video outpaces what the evidence actually supports. Most of the relevant research is in animal models, not humans, and injection site pharmacokinetics for these specific peptides have not been rigorously studied in controlled human trials.

BPC-157's tissue-repair properties have been documented in rodent studies. Sikiric et al. (2018, Current Pharmaceutical Design) showed wound-healing and tendon-repair effects in rats across multiple administration routes, including subcutaneous and intraperitoneal. The idea that localized subcutaneous injection creates meaningful regional concentration is biologically plausible, but it has not been confirmed in human pharmacokinetic studies. The creator presents this as more settled than it is.

TB-500, the synthetic version of thymosin beta-4, does have mechanistic support for systemic action. Goldstein and Kleinman (2015, Annals of the New York Academy of Sciences) reviewed its roles in actin sequestration, anti-inflammation, and tissue repair across multiple organ systems. Faster systemic delivery via intramuscular injection is pharmacologically reasonable, given that muscle tissue is highly vascularized. But again, direct human data on IM versus subcutaneous absorption for TB-500 specifically is thin.

What did they get wrong (or right)?

Credit where it is due: the basic pharmacology framing is defensible. Intramuscular injections do generally produce faster absorption than subcutaneous ones, and TB-500's mechanism does suggest systemic rather than purely local action. Those are not controversial statements.

What he gets wrong, or at minimum overstates, is the localized concentration effect for BPC-157. The claim that injecting "close to a damaged tendon, joint, or muscle belly" creates a meaningfully higher regional concentration before systemic distribution is speculative. Subcutaneous peptide absorption is primarily lymphatic, and localized tissue concentration gradients for small peptides like BPC-157 have not been demonstrated in human tissue studies. This is a plausible hypothesis, not established protocol.

He also calls TB-500 "thiamisin beta-4," which appears to be a mispronunciation of thymosin beta-4. Small error, but worth noting for a creator positioning himself as an expert source. More significantly, framing all of this as optimization science while selling access to a paid "BP90 ecosystem" creates a commercial context that viewers should factor into how they weigh the advice.

What should you actually know?

BPC-157 and TB-500 are unscheduled research peptides in many countries but are not approved by the FDA for human use. Neither has completed Phase 3 human clinical trials for any indication. Using them involves real regulatory and safety unknowns that a 3-minute TikTok video cannot adequately address.

The injection site discussion is not useless. Pharmacokinetic principles do apply, and the creator's general framework is reasonable. But the precision implied here, that a specific injection location near an injury produces a clinically meaningful local effect, is not supported by human data. Anyone considering these compounds should work with a licensed clinician who can assess individual risk, not follow a social media optimization protocol.

• Both peptides require reconstitution and sterile injection technique. Improper handling creates real infection risk.
• Pre-mixed blends from unverified sources carry contamination and dosing accuracy concerns that the video does not address.
• The regulatory status of these compounds varies significantly by country, and "gray area" is not the same as legal or safe.